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Aim: The aim of this systematic review and meta-analysis was to determine if adjunct steroids affect
jaundice-free, cholangitis, and survival rates after Kasai portoenterostomy. Methods: The literature was
searched using the following terms: biliary atresia, portoenterostomy, steroids, glucocorticoids, dexa-
methasone, prednisolone, and hydrocortisone. The primary outcome was the jaundice-free rate. Sec-
ondary outcomes were cholangitis and survival rates. Results: Ten studies were included in the
systematic review and 8 in the meta-analyses. Steroid treatment regimens were inconsistent between
studies. The pooled odds ratio (OR) for the jaundice-free rate did not signiﬁcantly favor steroid over non-
steroid treatment (1.95; 95% conﬁdence interval [CI]: 0.91e4.11; P ¼ 0.087), nor did the pooled OR for the
cholangitis rate (0.75; 95% CI: 0.48e1.17; P ¼ 0.202). Overall survival ranged from 58 to 95% in the steroid
group and from 36 to 96% in the control group. Native liver survival ranged from 30 to 56% in the steroid
group and from 31 to 48% in the control group. The survival data were not suitable for meta-analysis.
Conclusions: Although these results imply that adjunct steroids after Kasai portoenterostomy for BA
may not improve jaundice-free or cholangitis rates, the quality of available evidence is limited and
therefore not deﬁnitive. Additional high quality studies are needed.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Biliary atresia (BA) is rare neonatal condition that has been re-
ported to occur in 1 in every 10,000 to 19,000 live births [1e4].
Interestingly, BA may be more common among East Asian pop-
ulations, with one Taiwanese study reporting an incidence of
approximately 1.8 in every 10,000 live births [5]. Pathologically, BA
is a progressive obliterative cholangiopathy that may affect both
the intra- and extrahepatic branches of the biliary tree [1,2]. The
major symptoms are cholestasis, ﬁbrosis, and cirrhosis. If left un-
treated, BAultimately leads to portal hypertension, liver failure, and
death by two years of age [1,2].).
by Elsevier Ltd. All rights reservedThere are two treatments currently available for BA; Kasai por-
toenterostomy and liver transplantation [1,6]. Of these, Kasai por-
toenterostomy is the ﬁrst line treatment, the goal of which is to
facilitate bile ﬂow, clear jaundice, and normalize bilirubin levels
[1,6,7]. Despite being effective in a relatively large proportion of
cases [1], Kasai portoenterostomy is not a curative procedure, and
BA ultimately progresses (at variable rates) necessitating the need
for liver transplantation [2]. Indeed BA is the most common reason
for liver transplantation in children [1]. As the availability of donor
livers is always limited, optimizing the success Kasai portoenter-
ostomy is of paramount importance to improve overall rates of
survival among patients with BA.
Various adjuvant therapies have been given to patients after
Kasai portoenterostomy in an attempt to prevent complications
and therefore improve rates of procedural success [1,2]. Of note, in
addition to exerting anti-inﬂammatory and immunomodulatory
effects, corticosteroids have been purported to improve bile salt-.
Fig. 1. Flowchart of study selection.
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adjunct treatment with steroids after Kasai portoenterostomy. The
results from these studies, however, have been inconclusive, as
discussed in several review articles [1,2,7]. Further, the ﬁndings of a
systematic review and meta-analysis published in 2011 suggest
that adjuvant steroids do not facilitate the normalization of bili-
rubin levels six months after Kasai portoenterostomy or delay the
need for liver transplantation [8]. This meta-analysis, however, did
not examine other key factors related to successful treatment,
including jaundice-free or cholangitis rates.
To gain further information on the efﬁcacy of adjunct steroids
after Kasai portoenterostomy for BA, we conducted a systematic
review and meta-analysis of the available literature. The speciﬁc
aim of our study was to determine if adjunct steroids affect
jaundice-free, cholangitis, and survival rates.
2. Materials and methods
2.1. Search strategy
PubMed and The Cochrane Central Register of Controlled Trials
were searched using combinations of the following key terms:
biliary atresia, portoenterostomy, steroids, glucocorticoids, dexa-
methasone, prednisolone, hydrocortisone. The literature search
was performed on 30 April 2013.
2.2. Selection of studies
2.2.1. Inclusion criteria
Studies were considered for inclusion in the systematic review
and meta-analysis if they: were comparative studies; involved
patients with BA who underwent Kasai portoenterostomy and
received adjuvant steroid therapy; involved patients who had not
received liver transplantation; and reported on the effectiveness of
adjuvant steroid therapy.
2.2.2. Exclusion criteria
Studies were excluded from the systematic review and meta-
analysis if they: were single-arm studies; involved patients who
did not receive adjunct steroid therapy; or were reported as letter,
comment, editorial, or case report format articles.
2.3. Data extraction
Data were extracted from eligible studies by two independent
reviewers. A third reviewer was consulted to resolve any dis-
agreements between reviewers. Information/data extracted
included ﬁrst author and year of publication, study design, treat-
ment groups, number of patients, age and sex distribution of pa-
tients, and postoperative jaundice-free, cholangitis, and survival
rates.
2.4. Outcomes
The primary outcome of interest was the jaundice-free rate after
treatment. The secondary outcomes were the cholangitis and sur-
vival rates after treatment.
2.5. Quality assessment
The Newcastle-Ottawa scalewas used to assess the quality of the
nonrandomized studies included in the systematic review/meta-
analysis, whereas Delphi list was used to assess the quality of
randomized studies included in the systematic review/meta-
analysis.2.6. Statistical methods
Odds ratios (OR) with 95% conﬁdence intervals were calculated
for the jaundice-free and cholangitis rates and were compared
between patients who received adjunct steroid treatment (steroid
group) and those who did not receive adjunct steroid treatment
(control group). Meta-analysis of survival rate was not performed
due to the lack of appropriate/sufﬁcient data. Heterogeneity among
the studies was assessed by calculating the Cochran Q and the I [2]
statistic. For the Q statistic, P < 0.10 was considered to indicate
statistically signiﬁcant heterogeneity. The I2 statistic indicates the
percentage of the observed between-study variability caused by
heterogeneity. Heterogeneity determined using the I2 statistic was
deﬁned as follows: 0e24% ¼ no heterogeneity;
25e49%¼moderate heterogeneity; 50e74%¼ large heterogeneity;
and 75e100% ¼ extreme heterogeneity. If either the Q statistic
(P < 0.1) or I2 statistic (>50%) indicated heterogeneity existed be-
tween studies, a random-effects model of analysis (DerSimonian-
Laird method) was used. Otherwise, a ﬁxed-effects model of anal-
ysis (Mantel-Haenszel method) was used. Pooled ORs were calcu-
lated and two-sided P value <0.05 was considered to indicate
statistical signiﬁcance. Sensitivity analysis was performed for
jaundice-free and cholangitis rates based on the leave-one-out
approach. All statistical analyses were performed using the statis-
tical software Comprehensive Meta-Analysis, version 2.0 (Biostat,
Englewood, NJ).3. Results
3.1. Literature search
A total of 481 studies were identiﬁed in the literature search
(Fig. 1). Of these, 18 underwent full-text review and 8 were sub-
sequently excluded. Hence,10 studies [7,9e16] were included in the
systematic review (8 of these studies were included in the meta-
analysis). One study [13] was excluded from the meta-analyses
because there was a large difference in patient numbers in each
group, while the other [7] was excluded because the patients
involved partially overlapped with those included in a later study
[16].
Table 2
Outcomes reported in studies included in the systematic review.
Author (year) Jaundice-free (S vs C,
%)
Cholangitis (S vs
C, %)
Survival (S vs C, %)
Davenport
(2013)
High dose: 67
Low dose: 66
No steroid: 52 (6
months)
NA OS high dose: 95
OS low dose: 94
OS No steroid: 96 (4
years)
NLS high dose: 56
NLS low dose: 50
NLS No steroid: 48 (4
years)
Escobar (2006) NA 57 vs 59 OS: 86 vs 82
Davenport
(2007)
47 vs 49 (6 months) NA NA
Meyers (2003) 71 vs 8 28 vs 43 OS: 92 vs 38
Lao (2010) NA 9 vs 10 NA
Petersen
(2008)
30 vs 38 (6 months) 10 vs NA OS: 80 vs 76 (2 years)
NLS: 30 vs 31 (2 years)
Vejchapipat
(2007)
61 vs 50 (6 months) 39 vs 55 NA
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The characteristics of the studies included in the systematic
review are summarized in Table 1. Among the 10 studies included,
there was one randomized controlled trial [7], two prospective
studies [11,16], and seven retrospective studies [9,10,12e15,17]. The
total number of patients in the studies ranged from 27 to 516
(overall N ¼ 1229). The age of patients in the studies ranged from
approximately 40 days to more than 1 year. In general, a higher
proportion of patients in the studies were female than male.
Standard steroid regimens were used in six studies
[7,9,11,12,14e16], whereas regimens in the other three studies
[10,13,17] were variable and typically prescribed at the discretion of
treating physicians. The standard steroid regimens varied between
studies in terms of the type(s) of steroid given, dosing, and the
duration of treatment. Six studies [7,9,11,12,15,16] reported on other
adjuvant treatments, which were typically antibiotics, fat-soluble
vitamins, and ursodeoxycholic acid.Muraji (2004) NA NA OS: 58 vs 36
Chung (2008) NA 23 vs 41 NA
Kobayashi
(2005)
76 vs 58 NA NA
C, control treatment group; IV, intravenous; RCT, randomized controlled trial; NA,
not available; NLS, native liver survival; OS, overall survival; S, steroid treatment
group; wk, weeks.3.3. Study outcomes
The outcomes of the studies included in the systematic review
are summarized in Table 2.
Jaundice-freedom was deﬁned by a serum bilirubin concentra-
tion 20 mol/L in three studies [7,11,16] and <2.0 mg/mL in two
studies [12,15]. The study reported by Meyers et al. [9] did not
provide a deﬁnition of jaundice freedom. The study reported by
Vejchapipat et al. [12] was the only study to provide a deﬁnition of
cholangitis: a combination of fever >38.5 C, change from yellow to
alcholic stool, and leukocytosis with polymorphonuclear leukocyte
predominance.Table 1
Characteristics of studies included in the systematic review.
Author
(year)
Study design Number
of
patients
(S vs C)
Mean age (S vs C) Sex (S
vs C, %
male)
Steroid regimen
Davenport
(2013)
Prospective High
dose: 44
Low dose:
18
No
steroid:
91
Median
High dose: 46d
Low dose: 54d
No steroid: 50d
NA High dose: oral pred
e14; 3 mg/kg/d d 1
e29, then hydrocor
2.5 mg/kg once dail
Low dose: See Dave
Escobar
(2006)
Retrospective 21 vs 22 All: 6.1 wk All: 37 NA
Davenport
(2007)
RCT 36 vs 37 Median: 60 vs
54 d
All: 47 Oral prednisolone (2
Meyers
(2003)
Retrospective 13 vs 14 1 infant 13 wk, 1
infant 16 wk, all
others <12 wk
NA IV solumedrol (tape
e12 wk prednisone
Lao (2010) Retrospective 239 vs
277
<2months: 49%; 2
e11 months: 50%;
1 year: 1%
41 vs
39
NA
Petersen
(2008)
Prospective 20 vs 29 62 vs 57 d 55 vs
55
IV methylprednisolo
(10 mg/kg/d d 1e5,
Vejchapipat
(2007)
Retrospective 33 vs 20 85 vs 98 d 46 vs
60
Prednisolone (4 mg
days for 1e3 month
Muraji
(2004)
Retrospective 208 vs 14 NA NA NA
Chung
(2008)
Retrospective 13 vs 17 70 vs 63 d All: 37 Oral prednisolone (4
d for 2 wk, then 1 m
Kobayashi
(2005)
Retrospective 51 vs 12 NA All: 24 IV prednisolone (tap
e2 mg/kg/d from d
pale)
C, control treatment group; IV, intravenous; RCT, randomized controlled trial; NA, not aSix studies [7,9,11,12,15,16] reported jaundice-free rates, which
ranged from 30% to 76% in the steroid group and 8%e58% in the
control group. Jaundice-free rates were clearly higher in the steroid
group compared with the control group in four studies [9,12,15,16],
whereas there were no marked between group differencesOther adjuvants
nisolone (5 mg/kg/d d 5e9; 4 mg/kg/d d10
5e19; 2 mg/kg/d d 20e24; 1 mg/kg/d, d 25
tisone 2.5 mg/kg twice daily d 30e32;
y d 33e35
nport (2007)
Antibiotics, cholestyramine
phenobarbitone, fat-soluble vitamins,
medium-chain triglyceride formula
NA
mg/kg/d d 7e21, 1 mg/kg/d d 22e28) Antibiotics, phenobarbitone, fat-
soluble vitamins, medium-chain
triglyceride formula
r of 10, 8, 6, 5, 4, 3, 2 mg/kg/d), then 8
(2 mg/kg/d).
Antibiotics, ursodeoxycholic acid
NA
ne
1 mg/kg/d d 6e28)
Antibiotics, ursodeoxycholic acid, fat-
soluble vitamins, medium-chain
triglyceride formula
/kg/d for 3e4 d from on d 7, then alternate
s)
Antibiotics, ursodeoxycholic acid, fat-
soluble vitamin E
NA
mg/kg/d from d 7 for 2 wk, then 2 mg/kg/
g/kg/d for 2 wk)
NA
er of single course of 6e2, 10e2 or 20
7e3, or restart from 20 mg if stool turned
Ursodeoxycholic acid,
aminoethylsulfonic acid or
phenobarbitone
vailable; S, steroid treatment group; wk, weeks.
D. Zhang et al. / International Journal of Surgery 12 (2014) 1203e12091206detected in two studies [7,11]. The most pronounced between
group difference was reported by Meyers et al., [9] who found that
the jaundice-free rate was 71% in the steroid group compared with
8% in the control group. Six studies [9e12,14,17] reported chol-
angitis rates, which ranged from 9% to 57% in the steroid group and
10%e59% in the control group. Cholangitis rates were clearly lower
in the steroid group compared with the control group in three
studies [9,12,14], whereas there were no marked between group
differences detected in two studies [10,17]. Five studies
[9,11,13,16,17] reported overall survival rates, which ranged from
58% to 95% in the steroid group and from 36% to 96% in the control
group. Overall survival rates were clearly higher in the steroid
group compared with the control group in two studies [9,13],
whereas there were no marked between group differences detec-
ted in three studies [11,16,17]. Again, themost pronounced between
group difference was reported by Meyers et al. (92% vs 38%) [9].
Two studies reported native liver survival rates [11,16], which
ranged from 30% to 56% in the steroid group and from 31% to 48% in
the control group. Native liver survival rates were similar between
groups in both studies.
3.4. Meta-analysis
3.4.1. Jaundice-free rate
Five studies [9,11,12,15,16] were included in the meta-analysis of
jaundice-free rate. After pooling of data, there was found to be
signiﬁcant heterogeneity among the studies (Q ¼ 8.17, df ¼ 4,
P ¼ 0.085; I2 ¼ 51.06%); therefore, a random-effects model of
analysis was used. The pooled OR (1.95, 95% CI ¼ 0.91 to 4.11,
P ¼ 0.087, Fig. 2) did not signiﬁcantly favor steroid treatment over
control or vice versa.
3.4.2. Cholangitis rate
Five studies [9,10,12,14,17] were included in the meta-analysis of
cholangitis rate. After pooling of data, there was found to be no
signiﬁcant heterogeneity among the studies (Q ¼ 1.46, df ¼ 4,
P ¼ 0.833; I2 ¼ 0.0%); therefore, a ﬁxed-effects model of analysis
was used. The pooled OR (0.75, 95% CI¼ 0.48e1.17, P¼ 0.202, Fig. 3)
did not signiﬁcantly favor steroid treatment over control or vice
versa.
Note: Meta-analysis of survival rate was not performed due to
the lack of appropriate/sufﬁcient data.
3.5. Sensitivity analysis
The results of the sensitivity analysis, in which the studies were
omitted one-by-one, are summarized in Fig. 4. For the jaundice-freeFig. 2. Forest plot showing results for the meta-analysis of the jaundice-free rate among p
receive adjunct postoperative steroids. CI, conﬁdence interval.rate, the removal of the study reported by Petersen [11] affected the
pooled estimate and resulted in a statistically signiﬁcant ﬁnding
(OR ¼ 2.44, 95% CI ¼ 1.10e5.41, P ¼ 0.028, Fig. 4A). For the chol-
angitis rate, the direction andmagnitude of the pooled estimate did
not vary markedly with the removal of any study (Fig. 4B).
3.6. Quality assessment
The results of the NewcastleeOttawa quality assessment of the
nonrandomized studies [9e16] included in the systematic review
are summarized in Table 3. In general, the quality of these studies
was satisfactory. For the only randomized trial included in our
systematic review, the results of the quality assessment are as
follows: Was a method of randomization used? Information not
available; Were the groups similar at baseline regarding the most
important prognostic indicators? Yes; Were the eligibility criteria
speciﬁed? Yes;Was the outcome assessor blinded? Information not
available; Was the care provider blinded? Yes; Was the patient
blinded? Yes; Were point estimates and measures of variability
presented for the primary outcomemeasures? Yes; Did the analysis
include an intention-to-treat analysis? Yes.
4. Discussion
Successful Kasai portoenterostomy is the key to restoring bile
ﬂowand delaying the need for liver transplantation in patients with
BA. To this end, adjunct postoperative steroids have long been
thought (and prescribed) to improve success rates after Kasai por-
toenterostomy. This makes theoretical sense given that BA is an
inﬂammatory obstructive cholangiopathy. Nevertheless, there is
lack of deﬁnitive clinical evidence to support such treatment [18].
In the present systematic review and meta-analysis, which
included 10 studies and more than 1000 patients with BA, we
examined the effects of adjunct steroids vs no steroids on a number
of key outcomes after Kasai portoenterostomy, namely the
jaundice-free rate, cholangitis rate, and survival rate (systematic
review only). The ﬁndings of our meta-analysis are limited by the
quality of the available literature, but suggest that adjunct steroids
after Kasai portoenterostomy for BA may not provide a deﬁnitive
beneﬁt regarding jaundice-free and cholangitis rates compared
with no adjunct steroids.
The primary outcome in our study was the jaundice-free rate,
while secondary outcomes were cholangitis and survival rates. Of
note, the results of our meta-analysis indicated that neither the
jaundice-free nor cholangitis rates were signiﬁcantly improved
with steroid compared with no steroid (control) treatment. Sub-
sequent sensitivity analysis revealed that the meta-analysis ofatients with biliary atresia who underwent Kasai portoenterostomy and did vs did not
Fig. 3. Forest plot showing results for the meta-analysis of the cholangitis rate among patients with biliary atresia who underwent Kasai portoenterostomy and did vs did not
receive adjunct postoperative steroids. CI, conﬁdence interval.
Fig. 4. Results of sensitivity analysis examining the inﬂuence of individual studies on pooled estimates as determined using the leave-one-out approach: (A) Jaundice-free rate; (B)
Cholangitis rate. CI, conﬁdence interval.
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these ﬁndings must be interpreted with some degree of caution.
Our ﬁndings, however, are consistent with those from a previously
published systematic review and meta-analysis [8], in which it was
found that another key outcome pertaining to the success of Kasai
portoenterostomy, normalization of serum bilirubin levels at six
months, was not signiﬁcantly improved with adjunct postoperative
steroids (OR: 1.48; 95% conﬁdence interval: 0.67e3.28). In the same
meta-analysis, it was also found that adjunct steroids had no sig-
niﬁcant effect (OR: 0.59; 95% conﬁdence interval: 0.21e1.72) on the
requirement for liver transplantation within the ﬁrst year after
Kasai portoenterostomy. Hence, the ﬁndings from our meta-
analysis and those reported by Sarkhy et al. [8] suggest thatadjunct steroids after Kasai portoenterostomy for BA may not
improve a number of key indicators of treatment success, namely,
the jaundice-free and cholangitis rates, the normalization of bili-
rubin levels at 6 months, and the requirement for early liver
transplantation.
Our systematic review revealed no clear evidence of survival
beneﬁts following treatment with adjunct steroids after Kasai
portoenterostomy. This was true for both overall survival and
native liver survival. Indeed, only one study reported that steroid
treatment was associated with a pronounced increase in overall
survival compared with control treatment [9]. Interestingly, the
same study by Meyer et al. [9] was the only study to report a
marked difference in jaundice-free rate favoring steroid treatment.
Table 3
NewcastleeOttawa quality assessment scale.
1st AU (year) Escobar
(2006)
Davenport
M (2013)
Meyers
(2003)
Lao
(2010)
Petersen
(2008)
Vejchapipat
(2007)
Muraji
(2004)
Chung
(2008)
Kobayashi
(2005)
Selection
1) Representativeness of the exposed cohort
a) Truly representative of the average _______________ (describe) in the
community
* * * * * * * *
b) Somewhat representative of the average ______________ in the
community
c) Selected group of users eg nurses, volunteers
d) No description of the derivation of the cohort *
2) Selection of the non exposed cohort
a) Drawn from the same community as the exposed cohort * * * NA * * * *
b) Drawn from a different source
c) No description of the derivation of the non exposed cohort *
3) Ascertainment of exposure
a) Secure record (eg surgical records) * * * * * * * * *
b) Structured interview
c) Written self report
d) No description
4) Demonstration that outcome of interest was not present at start of study
a) Yes NA NA NA * NA NA NA NA
b) No *
Comparability
1) Comparability of cohorts on the basis of the design or analysis
a) Study controls for _treatment_ (select the most important factor) * * * NA * * * * *
b) Study controls for any additional factor (This criteria could be modiﬁed to
indicate speciﬁc control for a second important factor.)
Outcome
1) Assessment of outcome
a) Independent blind assessment * *
b) Record linkage * * * * * * *
c) Self report
d) No description
2) Was follow-up long enough for outcomes to occur
a) Yes (select an adequate follow up period for outcome of interest) * * * * * * NA * *
b) No
3) Adequacy of follow up of cohorts
a) Complete follow up - all subjects accounted for * * * * * * * *
b) Subjects lost to follow up unlikely to introduce bias - small number lost
- > ___ % (select an adequate %) follow up, or description provided of those
lost)
c) Follow up rate < ____% (select an adequate %) and no description of those
lost
*
d) No statement
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underlie these striking ﬁndings, which were not replicated to the
same extent in any other study. Unfortunately, the survival data
retrieved in our systematic review were not suitable for meta-
analysis due to a lack of homogeneity in other study characteris-
tics. As such, we suggest that further studies are needed to fully
evaluate the effects of adjunct steroids on overall and native liver
survival.
Our meta-analysis has a number of limitations that warrant
mention, all of which should be considered when interpreting our
ﬁndings. First, all but three of the studies were retrospective and
therefore may have had varying degrees of bias inherent with the
design. Our quality assessment of these retrospective studies,
however, did reveal that the vast majority met the speciﬁed quality
criteria. Nevertheless, additional prospective studies, in particular
randomized controlled trials, are needed to further elucidate the
efﬁcacy of adjunct steroids after Kasai portoenterostomy. Second,
there was obvious heterogeneity among the studies, particularly
with regards to the steroid treatment regimens. There was little
consistency between studies in the types of steroids given, the dose
of steroids, or the duration of treatment. Further, in several of the
studies, treatment was not standardized resulting in within-study
heterogeneity. Such heterogeneity (both within and between
studies) may have affected the outcomes and, as such, the results ofour meta-analysis. It is possible that certain adjunct steroid regi-
mens may be of beneﬁt and others of no or limited beneﬁt; the
available literature does not permit delineation on this issue.
Rigorously designed prospective studies are needed to elucidate
the importance (or lack thereof) of adjunct steroid regimens on the
success of Kasai portoenterostomy. Finally, not all of the studies
reported results for each outcomes of interest. As such, our meta-
analysis was limited by the availability of data.
In summary, although the results of our meta-analysis suggest
that adjunct steroids after Kasai portoenterostomy for BA may not
improve jaundice-free or cholangitis rates, the overall quality of the
available evidence is insufﬁcient to make any deﬁnitive clinical
recommendations. Given that adjunct corticosteroids will un-
doubtedly continue to be routinely prescribed, we owe it to current
and future patients to conduct appropriate studies to provide a
deﬁnitive answer as to whether such treatment is justiﬁed.Ethical approval
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